|
You
are here: Home: BCU 5|2003: Faculty
Disclosures
FACULTY DISCLOSURES
As a provider accredited by the ACCME, it is the policy of NL
Communications Inc to require the disclosure of any significant
financial interest or any other relationship the sponsor or faculty
members have with the manufacturer(s) of any commercial product(s)
discussed in an educational presentation. The presenting faculty
reported the following:
|
Mark
D Pegram, MD
|
Consultant: Aventis Pharmaceuticals Inc,
Genentech Inc, ChromaVision Medical Systems, Inc |
Paul
E Goss, MD, PhD, FRCP(CA), FRCP(UK)
|
Grants/Research Support/Speakers’ Bureau: Novartis
Pharmaceuticals Corporation, Schering Plough Corporation, Pharmacia
Corporation, Pfizer Inc, Biomedicine |
Kathleen
I Pritchard, MD
|
Grants/Research Support/Speakers’ Bureau/Consultant:
AstraZeneca Pharmaceuticals LP, Pharmacia Corporation |
Generosa
Grana, MD
|
Speakers’ Bureau: AstraZeneca Pharmaceuticals
LP, Aventis Pharmaceuticals Inc |
Pharmaceutical
agents discussed in this program
|
| GENERIC |
TRADE |
MANUFACTURER |
| alendronate |
Fosamax® |
Merck & CompanyInc |
| anastrozole |
Arimidex® |
AstraZeneca Pharmaceuticals LP |
| bevacizumab |
AvastinTM |
Genentech Inc |
| capecitabine |
Xeloda® |
Roche Laboratories Inc |
| carboplatin |
Paraplatin® |
Bristol-Myers Squibb Company |
| celecoxib |
Celebrex® |
Pfizer Inc |
| cisplatin |
Platinol® |
Bristol-Myers Squibb Company |
| clodronate |
Various |
Various |
| cyclophosphamide |
Cytoxan® |
Bristol-Myers Squibb Company |
| |
Neosar® |
Pfizer Inc |
| docetaxel |
Taxotere® |
Aventis Pharmaceuticals Inc |
| doxorubicin |
Adriamycin® |
Pfizer Inc |
| doxorubicin HCL liposome injection |
Doxil® |
Ortho Biotech Products LP |
| epirubicin hydrochloride |
Ellence® |
Pfizer Inc |
| erlotinib (OSI-774) |
TarcevaT |
Genentech Inc, OSI Pharmaceuticals, Hoffman-LaRoche
Ltd |
| epoetin alpha |
Procrit®, Epogen® |
Ortho Biotech Products LP, Amgen Inc |
| estradiol |
Various |
Various |
| exemestane |
Aromasin® |
Pfizer Inc |
| filgrastim |
Neupogen® |
Amgen Inc |
| fluorouracil, 5FU |
Various |
Various |
| fulvestrant |
Faslodex® |
AstraZeneca Pharmaceuticals LP |
| gemcitabine |
Gemzar® |
Eli Lilly & Company |
| gefitinib |
Iressa® |
AstraZeneca Pharmaceuticals LP |
| letrozole |
Femara® |
Novartis Pharmaceuticals Corporation |
| methotrexate |
Various |
Various |
| paclitaxel |
Taxol® |
Bristol-Myers Squibb Company |
| pegfilgrastim |
Neulasta® |
Amgen Inc |
| tamoxifen citrate |
Nolvadex® |
AstraZeneca Pharmaceuticals LP |
| trastuzumab |
Herceptin® |
Genentech Inc |
| vinorelbine |
Navelbine® |
GlaxoSmithKline |
| zoledronic acid/zoledronate |
Zometa® |
Novartis Pharmaceuticals Corporation |
|
| |
This educational activity contains discussion of published and/or
investigational uses of agents that are not indicated by the FDA.
NL Communications Inc does not recommend the use of any agent outside
of the labeled indications. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications and warnings. The opinions expressed are those
of the presenters and are not to be construed as those of the publisher
or grantor.
|
|
|
|
